Any current/future new fundraising through debt or equity?

There is no mention of any current or planned new fundraising through debt or equity in the transcript. Dilip Shanghvi stated that the company is sitting on about $2 billion of cash and cash equivalents plus generating over $1 billion annual cash flow. The company does not have plans to return cash to shareholders via buybacks or dividends because it sees good investment opportunities. The focus is on investing the cash to generate double-digit returns on investment. No indication or discussion of raising new capital through debt or equity was provided during the call.

Any current/future capex/capital investment/strategic investment?

Sun Pharma is currently sitting on about $2 billion of cash and cash equivalents and generates over $1 billion in annual cash flow. There is no plan to return excess cash to shareholders via buybacks or increased dividends; instead, the company intends to seek appropriate investment opportunities. Recent market corrections have presented interesting investment opportunities that the company aims to work on. The company continues to invest in building its R&D pipeline for both Global Generics and Specialty businesses, with consolidated R&D spend at 6.8% of sales in Q3 FY24. Specialty R&D accoun

Future growth expectations in sales/revenue/volumes?

India Business: Sun Pharma grew 11.4% in Q3 FY24, outperforming the Indian Pharmaceutical Market (IPM). Growth was driven by both volume and new product launches (~2/3 of growth). The company aims to grow in line with or better than the market, but market-wide volume recovery for next year remains uncertain. U.S. Specialty Business: Strong growth expected, driven by products like Ilumya, CEQUA, and Levulan. Incremental P&L investments planned to support growth, tailored by product and market. Emerging Markets: Underlying constant currency growth was about 5.2% year-on-year in Q3 FY24. Re

Future growth expectations in earnings/operating earnings/profits/EPS?

Sun Pharma reported a 19.7% growth in adjusted net profit for Q3 FY24 compared to Q3 FY23, with EBITDA margin improving to 28.1%. Management indicated no immediate need to revise guidance despite high single-digit growth in the last quarter. Dividend policy of 30-35% payout will continue, with no plans to return excess cash to shareholders; instead, focus is on investment opportunities to generate double-digit returns. Specialty business and new products like Ilumya, CEQUA, and Winlevi are expected to drive growth with incremental P&L investments. India business aims to grow in line with or be

Sun Pharma.Inds.Q3 FY24Pharmaceuticals & Biotechnology

Sun Pharma.Inds. Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,801P/E: 35.2Market Cap: ₹4.4L CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 4

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 4

India Business: Sun Pharma grew 11.4% in Q3 FY24, outperforming the Indian Pharmaceutical Market (IPM). Growth was driven by both volume and new product launches (~2/3 of growth). The company aims to grow in line with or better than the market, but market-wide volume recovery for next year remains uncertain.
U.S. Specialty Business: Strong growth expected, driven by products like Ilumya, CEQUA, and Levulan. Incremental P&L investments planned to support growth, tailored by product and market.
Emerging Markets: Underlying constant currency growth was about 5.2% year-on-year in Q3 FY24.
Rest of the World: 12.9% sales growth in Q3 FY24, continued investment in pipeline expected.
Specialty products, including Ilumya, continue to be in the growth phase, with expectations to sustain momentum.
Overall, a growth-oriented budget is planned with investments in sales, marketing, and product development to maintain growth trajectory.

Margin guidance

Category 3

Sun Pharma reported a 19.7% growth in adjusted net profit for Q3 FY24 compared to Q3 FY23, with EBITDA margin improving to 28.1%.
Management indicated no immediate need to revise guidance despite high single-digit growth in the last quarter.
Dividend policy of 30-35% payout will continue, with no plans to return excess cash to shareholders; instead, focus is on investment opportunities to generate double-digit returns.
Specialty business and new products like Ilumya, CEQUA, and Winlevi are expected to drive growth with incremental P&L investments.
India business aims to grow in line with or better than the overall market, with focus on volume growth and new product launches.
Emerging markets face currency hedging challenges, but underlying constant currency growth is positive.
R&D spend expected around 6.8% of sales with continued investment in pipeline development.
Overall, Sun Pharma expects to maintain steady growth with strategic investments supporting future earnings expansion.

See what Sun Pharma.Inds. management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no mention of any current or planned new fundraising through debt or equity in the transcript.
Dilip Shanghvi stated that the company is sitting on about $2 billion of cash and cash equivalents plus generating over $1 billion annual cash flow.
The company does not have plans to return cash to shareholders via buybacks or dividends because it sees good investment opportunities.
The focus is on investing the cash to generate double-digit returns on investment.
No indication or discussion of raising new capital through debt or equity was provided during the call.

Order book

The transcript from the Sun Pharma Q3 FY24 earnings call does not explicitly mention details about the current or expected order book or pending orders. The discussion primarily focuses on: - Financial performance highlights, including sales growth and market share. - Business updates on segments like U.S. Specialty, India formulations, Emerging Markets, and Rest of the World. - Pipeline progress and R&D investments. - Product-specific questions related to Ilumya, GLP-1, Nidlegy, and supply chain issues. - Hedging policies and cash deployment strategies. - No direct references or disclosures about specific current or expected order book values or pending orders were made during the call or in the provided transcript excerpt. If you need detailed order book information, it might be available in other company reports or investor presentations.

See what Sun Pharma.Inds. management said on order book — free account, 30 seconds.

Capex plans

Yes

Sun Pharma is currently sitting on about $2 billion of cash and cash equivalents and generates over $1 billion in annual cash flow.
There is no plan to return excess cash to shareholders via buybacks or increased dividends; instead, the company intends to seek appropriate investment opportunities.
Recent market corrections have presented interesting investment opportunities that the company aims to work on.
The company continues to invest in building its R&D pipeline for both Global Generics and Specialty businesses, with consolidated R&D spend at 6.8% of sales in Q3 FY24.
Specialty R&D accounted for 39.2% of total R&D spend in the quarter.
There is ongoing development of specialty products such as GL0034 and pipeline progression indicated, with more detailed R&D guidance expected next year.

Track Sun Pharma.Inds. — get its next earnings analysis in your feed

How does Sun Pharma.Inds. rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisSun Pharma.Inds.

Rev 4Mar 3

See where Sun Pharma.Inds. sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Sun Pharma.Inds. rank in Pharmaceuticals & Biotechnology?

Compare Sun Pharma.Inds. against every Pharmaceuticals & Biotechnology company (Q3 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Sun Pharma.Inds.'s management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd vs Zydus Lifesci.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →